SEC 13F Intelligence

Managers / Q2 2020 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value
$183M
Q2 2020
Positions
127
Filings on Record
12
2019–present window
Filed
Aug 12, 2020
original filing

Summary

Knott David M reported $183M in U.S.-listed holdings across 127 positions for Q2 2020.

Its largest position, LGND, represents 16.0% of the portfolio.

Compared with Q1 2020, the fund opened 11 new positions and exited 40.

Portfolio Metrics

Turnover
+16.3%
vs prior filed quarter
Top-10 Concentration
+60.0%
share of reported value
Largest Position
+16.0%
Ligand Pharmaceuticals Incorporated
New / Exited
11 / 40
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $213MQ4 ’18Q1 ’19: $251MQ2 ’19: $237MQ2 ’19Q3 ’19: $238MQ4 ’19: $247MQ4 ’19Q1 ’20: $158MQ2 ’20: $183MQ2 ’20Q3 ’20: $170MQ4 ’20: $221MQ4 ’20Q1 ’21: $234MQ2 ’21: $281MQ2 ’21Q3 ’21: $275Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 83.6%Other: 6.7%Ltd Part: 5.0%MLP: 4.2%REIT: 0.5%Other: 0.1%
  • Common Stock · 83.6% · $153M
  • Other · 6.7% · $12M
  • Ltd Part · 5.0% · $9M
  • MLP · 4.2% · $8M
  • REIT · 0.5% · $945,000
  • Other · 0.1% · $113,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
FTAIEURFortress Trans & Infrastructure Inv. LLCNEW+700.0K700.0K+$9M$9M
FSKFS KKR Capital Corp.NEW+395.2K395.2K+$6M$6M
Kennedy-Wilson Holdings, Inc.NEW+210.0K210.0K+$3M$3M
TGTXTG Therapeutics Inc.NEW+12.0K12.0K+$234,000$234,000
CYTKCytokinetics IncorporatedNEW+8.9K8.9K+$210,000$210,000
RLMDRelmada Therapeutics, Inc.NEW+3.0K3.0K+$134,000$134,000
TARAProtara Therapeutics, Inc.NEW+3.8K3.8K+$112,000$112,000
CUZCousins PropertiesNEW+3.4K3.4K+$100,000$100,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

47 positions
#IssuerClass% PortfolioValueShares
1LGNDLigand Pharmaceuticals Incorporatedhistory →Common16.56%$30M271.2K
2SRCLEURStericycle, Inc.history →Common8.22%$15M269.1K
3APOEURApollo Global Management, Inc.history →Common8.18%$15M300.0K
4UPLDEURUpland Software, Inc.history →Common7.71%$14M406.5K
5FTAIEURFortress Trans & Infrastructure Inv. LLChistory →Common4.96%$9M700.0K
6GOOGAlphabet Inc-Cl Chistory →Common4.32%$8M5.6K
7KKRKKR & Co. Inc.history →Common3.03%$6M180.0K
8FSKFS KKR Capital Corp.history →Common2.67%$5M350.0K
9Calumet Specialty Products Partners, LPCommon2.49%$5M2.00M
10CCXIEURChemoCentryx, Inc.history →Common2.36%$4M75.0K
11PFEPfizer Inc.history →Common2.35%$4M131.9K
12LKQ1LKQ Corporationhistory →Common2.15%$4M150.0K
13ABBVAbbVie Inc.history →Common1.76%$3M32.8K
14Kennedy-Wilson Holdings, Inc.Common1.74%$3M210.0K
15ZGNXEURZogenix, Inc.history →Common1.56%$3M105.6K
16BMYBristol-Myers Squibb Companyhistory →Common1.49%$3M46.4K
17CLDNEUREiger BioPharmaceuticals, Inc.history →Common1.38%$3M263.7K
18BLUBELLUS Health Inc.history →Common1.35%$2M238.6K
19KDMNKadmon Holdings, Inc.history →Common1.22%$2M437.6K
20BioDelivery Sciences International, Inc.Common1.20%$2M505.5K
21JPMJP Morgan Chasehistory →Common1.18%$2M23.1K
22TREURTrillium Therapeutics Inc.history →Common1.17%$2M264.2K
23XENEXenon Pharmaceuticals Inc.history →Common1.16%$2M169.0K
24Horizon Therapeutics Public Ltd. CompanyCommon1.11%$2M36.5K
25BCRXBioCryst Pharmaceuticals, Inc.history →Common1.03%$2M397.4K
26CHRSCoherus Biosciences, Inc.history →Common1.02%$2M104.6K
27AUPHAurinia Pharmaceuticals Inc.history →Common1.02%$2M114.8K
28MPLXMPLX LPCommon0.94%$2M100.0K
29VKTXViking Therapeutics, Inc.Common0.86%$2M218.1K
30Cidara Therapeutics, Inc.Common0.82%$2M407.1K
31ABAllianceBernstein Holdings PL Unit LtdCommon0.73%$1M49.0K
32COLLCollegium Pharmaceutical, Inc.Common0.66%$1M69.1K
33Alkermes PLCCommon0.62%$1M58.1K
34Strongbridge Biopharma PLCCommon0.61%$1M296.0K
35Quotient LimitedCommon0.52%$959,000129.5K
36BACVerizon Communications Inc.Common0.51%$937,00017.0K
37uniQure N.V.Common0.50%$917,00020.4K
38International Gaming TechnologiesCommon0.49%$890,000100.0K
39KMBKimberly Clark CorporationCommon0.46%$848,0006.0K
40JNJJohnson & JohnsonCommon0.39%$714,0005.1K
41MDLZMondelez Int'l Inc.Common0.36%$665,00013.0K
42TAT&T Inc.Common0.33%$605,00020.0K
43RDUSEURRadius Health Inc.Common0.32%$587,00043.0K
44ADMAADMA Biologics, Inc.Common0.32%$586,000200.2K
45DWDPEURDupont De Nemours Inc.Common0.31%$564,00010.6K
46IBMInternational Business MachinesCommon0.28%$517,0004.3K
47ALIMEURAlimera Sciences, Inc.Common0.28%$505,00080.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$275M197Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$281M195Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$234M166May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$221M145Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$170M135Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$183M127Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$158M156May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$247M152Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$238M157Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$237M148Aug 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$251M143May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$213M133Feb 12, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.